Brand/Generic Settlement Reform Will Be Balancing Act For Congress
Development of legislation to address settlements between brand and generic companies will need to ensure that commercial incentives remain for generic firms to challenge patents
You may also be interested in...
Apotex could make its case for scrapping first-to-file exclusivity during a hearing in Rep. Rush’s subcommittee.
Among a number of potential congressional actions that could benefit the generic industry, generic manufacturers appear to be most bullish about the prospects for the establishment of a pathway for follow-on biologics
After relatively smooth sailing through the Senate Judiciary Committee, legislation to prohibit "reverse payments" in brand/generic settlements now faces the challenge of securing floor-time for consideration by the full chamber